The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since ...

Initial $75M Series A investment from founding investors Atlas Venture, LAV and venBio in April 2025, recently augmented by $37.5M Series A-1 funding led by Omega Funds, with participation from ...

Cambridge, USA-based clinical-stage biotechnology company Caldera Therapeutics, which is developing the first-in-class ...

During the J.P. Morgan Healthcare Conference, VIVUS will share key highlights from 2025, demonstrating our commitment to advancing innovative clinical therapies across a variety of conditions,” said ...

NUBURU, Inc. , a global pioneer in high-performance blue laser technology, today announced a significant advancement in its strategic partnership with Tekne S.p.A. ("Tekne"), following the execution ...

Future Pak becomes exclusive U.S. marketer for Mytesi® and Canalevia®-CA1 Meaningful non-dilutive capital enables Jaguar to ...

Insilico Medicine ("Insilico"), a clinical-stage, generative AI-driven drug discovery company, today announced the completion of first patient first dose in BETHESDA: a Phase IIa clinical trial of ...

According to MarketsandMarkets™, the Human Microbiome Drugs Market is projected to grow from about USD 0.35 billion in 2025 ...

While there are many benefits of strength training that don’t involve changing your body composition, experts often recommend ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 4 undervalued ...

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected ...

Margaret Cho reflected on the time she had an accident while performing due to the weight loss drug she used to take: “I ...